Alliance for Sleep Clinical Practice Guideline on Switching or Deprescribing Hypnotic Medications for Insomnia

• Published in: Journal of clinical medicine Vol. 12; no. 7; p. 2493
• Main Authors: Watson, Nathaniel F, Benca, Ruth M, Krystal, Andrew D, McCall, William V, Neubauer, David N
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25.03.2023; MDPI
• Subjects: Anesthesia; Antidepressants; Anxiety; Benzodiazepines; Clinical medicine; Clinical practice guidelines; Comorbidity; Dosage and administration; Drug dosages; Drug therapy; Drug withdrawal; Hypnotics; Insomnia; Practice guidelines (Medicine); Psychotropic drugs; Review; Sedatives; Sleep; United States; United States > US; switching; insomnia medications; hypnotics; deprescribing; insomnia
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12072493

Determining the most effective insomnia medication for patients may require therapeutic trials of different medications. In addition, medication side effects, interactions with co-administered medications, and declining therapeutic efficacy can necessitate switching between different insomnia medications or deprescribing altogether. Currently, little guidance exists regarding the safest and most effective way to transition from one medication to another. Thus, we developed evidence-based guidelines to inform clinicians regarding best practices when deprescribing or transitioning between insomnia medications. Five U.S.-based sleep experts reviewed the literature involving insomnia medication deprescribing, tapering, and switching and rated the quality of evidence. They used this evidence to generate recommendations through discussion and consensus. When switching or discontinuing insomnia medications, we recommend benzodiazepine hypnotic drugs be tapered while additional CBT-I is provided. For Z-drugs zolpidem and eszopiclone (and not zaleplon), especially when prescribed at supratherapeutic doses, tapering is recommended with a 1-2-day delay in administration of the next insomnia therapy when applicable. There is no need to taper DORAs, doxepin, and ramelteon. Lastly, off-label antidepressants and antipsychotics used to treat insomnia should be gradually reduced when discontinuing. In general, offering individuals a rationale for deprescribing or switching and involving them in the decision-making process can facilitate the change and enhance treatment success.